Apatorsen sodium

Modify Date: 2025-08-26 11:30:05

Apatorsen sodium structure	Common Name	Apatorsen sodium
	CAS Number	915443-09-3	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Apatorsen sodium

Apatorsen (sodium) is an antisense oligonucleotide designed to bind to Hsp27 mRNA, resulting in the inhibition of the production of Hsp27 protein.

Name	Apatorsen sodium

Description	Apatorsen (sodium) is an antisense oligonucleotide designed to bind to Hsp27 mRNA, resulting in the inhibition of the production of Hsp27 protein.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> HSP Signaling Pathways >> Cell Cycle/DNA Damage >> HSP
References	[1]. Yu EY, Ellard SL, Hotte SJ, et al. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 2018;36(2):278-287. [2]. Spigel DR, Shipley DL, Waterhouse DM, et al. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. Oncologist. 2019;24(12):e1409-e1416.

Description

Apatorsen (sodium) is an antisense oligonucleotide designed to bind to Hsp27 mRNA, resulting in the inhibition of the production of Hsp27 protein.

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Metabolic Enzyme/Protease >> HSP

Signaling Pathways >> Cell Cycle/DNA Damage >> HSP

References

[1]. Yu EY, Ellard SL, Hotte SJ, et al. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 2018;36(2):278-287.

[2]. Spigel DR, Shipley DL, Waterhouse DM, et al. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. Oncologist. 2019;24(12):e1409-e1416.

InChIKey	DGMKQBWICZTTBN-OWXIQQMWSA-A
SMILES	COCCOC1C(O)C(COP([O-])(=S)OC2C(COP([O-])(=S)OC3C(COP([O-])(=S)OC4C(COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cc(C)c(=O)[nH]c6=O)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5C(COP([O-])(=S)OC6C(COP([O-])(=S)OC7C(COP([O-])(=S)OC8C(CO)OC(n9cnc%10c(=O)[nH]c(N)nc%109)C8OCCOC)OC(n8cnc9c(=O)[nH]c(N)nc98)C7OCCOC)OC(n7cnc8c(=O)[nH]c(N)nc87)C6OCCOC)OC(n6cnc7c(N)ncnc76)C5OCCOC)OC(n5cc(C)c(=O)[nH]c5=O)C4OCCOC)OC(n4cc(C)c(N)nc4=O)C3OCCOC)OC(n3cnc4c(=N)[nH]cnc43)C2OCCOC)OC1n1cc(C)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

InChIKey

DGMKQBWICZTTBN-OWXIQQMWSA-A

SMILES

COCCOC1C(O)C(COP([O-])(=S)OC2C(COP([O-])(=S)OC3C(COP([O-])(=S)OC4C(COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cc(C)c(=O)[nH]c6=O)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5CC(n6cnc7c(=O)[nH]c(N)nc76)OC5COP([O-])(=S)OC5CC(n6cc(C)c(N)nc6=O)OC5COP([O-])(=S)OC5C(COP([O-])(=S)OC6C(COP([O-])(=S)OC7C(COP([O-])(=S)OC8C(CO)OC(n9cnc%10c(=O)[nH]c(N)nc%109)C8OCCOC)OC(n8cnc9c(=O)[nH]c(N)nc98)C7OCCOC)OC(n7cnc8c(=O)[nH]c(N)nc87)C6OCCOC)OC(n6cnc7c(N)ncnc76)C5OCCOC)OC(n5cc(C)c(=O)[nH]c5=O)C4OCCOC)OC(n4cc(C)c(N)nc4=O)C3OCCOC)OC(n3cnc4c(=N)[nH]cnc43)C2OCCOC)OC1n1cc(C)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Apatorsen sodium
Price: Check
Purity: 98.0%
Delivery: 10 Day
Contact: Yang
Email: sales@echemcloud.com

DC Chemicals Limited
China
Product Name: Apatorsen sodium
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Delivery: 3 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

Get all suppliers and price by the below link:

Apatorsen sodium suppliers

Apatorsen sodium price

Apatorsen sodium

Use of Apatorsen sodium

Names

Apatorsen sodium Biological Activity

Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.